Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H13N3O2 |
Molecular Weight | 267.2826 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=CC=C1C(=O)C(C#N)C(=O)NC2=CC=CC=C2
InChI
InChIKey=KBQUAIAGRLAZGP-UHFFFAOYSA-N
InChI=1S/C15H13N3O2/c1-18-9-5-8-13(18)14(19)12(10-16)15(20)17-11-6-3-2-4-7-11/h2-9,12H,1H3,(H,17,20)
Molecular Formula | C15H13N3O2 |
Molecular Weight | 267.2826 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Prinomide is a carbamoylpyrrolepropionitrile derivative patented by Ciba-Geigy A.-G. as a nonsteroidal anti-inflammatory drug that has disease-modifying activity in rheumatoid arthritis. In clinical trials, Prinomide demonstrate significant improvement in symptom score and laboratory variables.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effect of a new antirheumatic drug (CGS10787B) on antibody formation and delayed-type hypersensitivity in BALB/c mice. | 1988 |
|
Prinomide tromethamine pharmacokinetics: mutually dependent saturable and competitive protein binding between prinomide and its own metabolite. | 1993 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8430060
250, 500, and 1000 mg every 12 hr for 28 days to healthy male volunteers.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:14:02 GMT 2023
by
admin
on
Fri Dec 15 15:14:02 GMT 2023
|
Record UNII |
6NHC09L02I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:14:02 GMT 2023 , Edited by admin on Fri Dec 15 15:14:02 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2111033
Created by
admin on Fri Dec 15 15:14:02 GMT 2023 , Edited by admin on Fri Dec 15 15:14:02 GMT 2023
|
PRIMARY | |||
|
C052921
Created by
admin on Fri Dec 15 15:14:02 GMT 2023 , Edited by admin on Fri Dec 15 15:14:02 GMT 2023
|
PRIMARY | |||
|
60352
Created by
admin on Fri Dec 15 15:14:02 GMT 2023 , Edited by admin on Fri Dec 15 15:14:02 GMT 2023
|
PRIMARY | |||
|
100000081088
Created by
admin on Fri Dec 15 15:14:02 GMT 2023 , Edited by admin on Fri Dec 15 15:14:02 GMT 2023
|
PRIMARY | |||
|
C73833
Created by
admin on Fri Dec 15 15:14:02 GMT 2023 , Edited by admin on Fri Dec 15 15:14:02 GMT 2023
|
PRIMARY | |||
|
6NHC09L02I
Created by
admin on Fri Dec 15 15:14:02 GMT 2023 , Edited by admin on Fri Dec 15 15:14:02 GMT 2023
|
PRIMARY | |||
|
77639-66-8
Created by
admin on Fri Dec 15 15:14:02 GMT 2023 , Edited by admin on Fri Dec 15 15:14:02 GMT 2023
|
PRIMARY | |||
|
6045
Created by
admin on Fri Dec 15 15:14:02 GMT 2023 , Edited by admin on Fri Dec 15 15:14:02 GMT 2023
|
PRIMARY | |||
|
SUB10047MIG
Created by
admin on Fri Dec 15 15:14:02 GMT 2023 , Edited by admin on Fri Dec 15 15:14:02 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |